H2 2015 Hypertension Pipeline Market Review

Hypertension Pipeline Market Companies Involved in Therapeutics Development are A1M Pharma AB, AbbVie Inc., Ache Laboratorios Farmaceuticos S/A, Actelion Ltd, Afferent Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Anacor Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Asahi Kasei Pharma Corp., Ascendis Pharma A/S, Bayer AG, Bial - Portela & Ca, S.A., Bio-inRen, Biolab Sanus Farmaceutica Ltda., BioLineRx, Ltd., Cardioxyl Pharmaceuticals, Inc., Carolus Therapeutics, Inc., Cellceutix Corporation, Celsion Corporation, China Grand Wuhan General Pharmaceutical Research Institute, Chong Kun Dang Pharmaceutical Corp., CJ HealthCare Corp., Complexa, Inc., Conatus Pharmaceuticals Inc., Corridor Pharmaceuticals Inc., Cytokinetics, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, DiaMedica Inc., Dong-A Socio Group, Eli Lilly and Company, Esperion Therapeutics, Inc., Galectin Therapeutics, Inc., Gilead Sciences, Inc., GlaxoSmithKline Plc, Glenveigh Medical, LLC, HanAll Biopharma Co., Ltd., Hanmi Pharmaceuticals, Co. Ltd., Innopharmax Inc., Insmed Incorporated, IntelGenx Corp., Intercept Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Jeil Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., JW Pharmaceutical Corporation, Kowa Company, Ltd., Lacer, S.A., Lee's Pharmaceutical Holdings Limited, Les Laboratoires Servier SAS, LG Life Science LTD., LinXis B.V., Lotus Pharmaceutical Co., Ltd., LTT Bio-Pharma Co., Ltd., Merck & Co., Inc., Mezzion Pharma Co. Ltd., miRagen Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation, Neurim Pharmaceuticals Ltd, Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis AG, Noxamet Ltd, Omeros Corporation, Ono Pharmaceutical Co., Ltd., Peloton Therapeutics, Inc., Pfizer Inc., PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pluristem Therapeutics Inc., Proteo, Inc. (Inactive), Pulmokine, Inc., Quantum Genomics SA, Reata Pharmaceuticals, Inc., RedHill Biopharma Ltd., Respira Therapeutics, Inc., rEVO Biologics, Inc., Sanofi, Selten Pharma, Inc, Serodus ASA, Sihuan Pharmaceutical Holdings Group Ltd., Silence Therapeutics Plc, Simcere Pharmaceutical Group, Sinoxa Pharma GmbH, SteadyMed Therapeutics, Inc., Suda Ltd, Sumitomo Dainippon Pharma Co., Ltd., Sun Pharma Advanced Research Company Ltd., Symplmed, Inc., Takeda Pharmaceutical Company Limited, The Medicines Company, Theravance Biopharma, Inc., Toray Industries, Inc., Torrent Pharmaceuticals Limited, TSH Biopharm Corporation Limited, vasopharm GmbH, VBS Pharmaceuticals, Vectura Group Plc, VG Life Sciences, Inc., Vicore Pharma AB and Yuhan Corporation.

Complete research report of 539 pages with TOC is available at

This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Inquire more about this research at


  • The report provides a snapshot of the global therapeutic landscape of Hypertension

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Hypertension and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Hypertension pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Hypertension

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline